RXRX · Recursion Pharmaceuticals
AI read · Good for RXRX
The AI's read
This gives Recursion a clearer route to test whether REC-4881 helps patients with FAP. The study will track polyp growth and removal, but it is not expected to start until the second half of 2027. Recursion estimates a possible $15 billion market, but that figure does not prove the drug will work or find buyers.